Risk factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia

Academic Emergency Medicine

Volumn 19, Issue 6, 2012, Pages 703-706

  Jenkins, Timothy C ^a,b,c   Sakai, Joy ^b   Knepper, Bryan C ^a   Swartwood, Claire J ^a,c   Haukoos, Jason S ^a,b,d   Long, Jeremy A ^a,b   Price, Connie S ^a,b,c   Burman, William J ^a,b,c  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Department of Civil and Environmental Engineering at Colorado State University and the Department of Environmental and Occupational Health at the Colorado School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ALCOHOLISM; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DIABETES MELLITUS; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE;

ACADEMIC MEDICAL CENTERS; ADULT; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; EMERGENCY SERVICE, HOSPITAL; HOSPITALS, URBAN; HUMANS; OUTPATIENT CLINICS, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; PNEUMONIA, PNEUMOCOCCAL; RETROSPECTIVE STUDIES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 84862247758     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2012.01365.x     Document Type: Article

References (12)

1. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis. 2005; 41:139-48. (Pubitemid 40962493)
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44(Suppl 2):S27-72. (Pubitemid 46290553)
3. Ambrose PG, Bast D, Doern GV, et al. Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public health concern: is it time to resight the goalposts? Clin Infect Dis. 2004; 39:1554-6.
4. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis. 2004; 38:655-62. (Pubitemid 38333861)
5. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med. 2004; 98:708-20. (Pubitemid 38842773)
6. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther. 2002; 24:736-51. (Pubitemid 34596943)
7. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58:377-82. (Pubitemid 36560938)
8. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003; 37:230-7. (Pubitemid 36930354)
9. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis. 2005; 40:1288-97. (Pubitemid 40570238)
10. Nava JM, Bella F, Garau J, et al. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clin Infect Dis. 1994; 19:884-90. (Pubitemid 24368826)
11. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005; 41:1254-60. (Pubitemid 41532667)
12. Grupper M, Potasman I. Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case. Am J Med Sci. 2008;335:141-4. (Pubitemid 351253411)